Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
Would you give adjuvant chemotherapy for adenoid cystic carcinoma of breast that is low ER positive, early stage, node negative?
Would you use oncotype to guide your decision?
Answer from: Medical Oncologist at Academic Institution
Simple answer: No.
Sign in or Register to read more
3431
Related Questions
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal type A on Mammaprint, after knowing that the patient had a poor response to neoadjuvant endocrine therapy?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?